Drugs@FDA application record, NDA 020449 (Taxotere, docetaxel) – supplement 28, efficacy new indication (2004)

Government Record · U.S. Food and Drug Administration, Center for Drug Evaluation and Research · May 19, 2004

U.S. Food et al., 2004-05-19: The FDA application record for NDA 020449 shows Sanofi Aventis US as holder and an action dated 19 May 2004 on supplement 28, an efficacy supplement adding a new indication – the prostate cancer indication based on TAX 327.

Efficacy-New Indication

HTML record, unpaginated

U.S. Food et al., 2004-05-19: The FDA application record for NDA 020449 shows Sanofi Aventis US as holder and an action dated 19 May 2004 on supplement 28, an efficacy supplement adding a new indication – the prostate cancer indication based on TAX 327. Funder: n/a (regulatory record). Maker: Sanofi Aventis US (Taxotere). Comparator: n/a. The 2004 approval label attached to SUPPL-28 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020449s028lbl.pdf) carries the new indication at page 17: 'Prostate Cancer: TAXOTERE in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.' A later supplement, SUPPL-29 (08/18/2004), added the adjuvant breast cancer indication, not a prostate one. Study type: regulatory record.